RankAlpha logo
Back to Rankings

ASRT

AssertioA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The announced cash merger leaves only a small spread to capture if the transaction closes on the announced terms; the 8-K confirms the $23.50 cash consideration and tender commencement. [#8-K-2026-05-18]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.2.
What can break
Closing mechanics around the 6.50% Convertible Senior Notes due 2027 add execution complexity because the merger triggers Fundamental Change and Make-Whole Fundamental Change rights. [#8-K-2026-05-18]
Momentum
94
Value
67
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $23.48 · Bull $23.50 · Bear $19.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $37.44
Why
Momentum94 · Δ7d -2.2
Value67 · Δ7d +0.2
Sentiment48 · Δ7d +7.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
+0.3
Value
67
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.2
Sentiment
48
33% active weight
Current posture
7d trendImproving
Δ7d
+7.1
Δ21d
+32.1
Why this grade

Composite grade A. Momentum 94.4 / Value 67.0 / Sentiment 48.1

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$151.41M
Beta
0.77
Shares Out
6.42M
P/E (TTM) · Derived
-102.6
P/S (TTM)
0.45
P/FCF (TTM)
4.63
Rev YoY
+69.4%
EPS YoY
+450.8%
Gross Margin
+68.2%
Op Margin
-22.9%
Net Debt
-$61.24M
Current Ratio
1.58
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology